-
State of open science in cancer research Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-18 Cristina Rius, Yiming Liu, Andrea Sixto-Costoya, Juan Carlos Valderrama-Zurián, Rut Lucas-Dominguez
-
Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-16 Ke Wang, Manyi Xu, Yanhua Wang, Chunwei Xu, Yue Hao, Zhengbo Song
-
Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-16 Yanhua Wang, Jingwen Wei, Manyi Xu, Jing Xiang, Keda Shao, Yue Hao, Zhengbo Song
-
An overview of current research on cancer stem cells: a bibliometric analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-16 Xueyang Zhang, Wenbo Du, Xizhi Huang, Haoting Zhong, Ning Hu
-
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-16 Yanqing Yang, Wei Chen, Lixian Dong, Lian Duan, Pengfei Gao
-
Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-14 Abdul Qahar Khan Yasinzai, Bisma Tareen, Katharine Tracy, Nimra Jamil, Marjan Khan, Hafeez Ullah, Muhammad Raza, Amin Ullah Khan, Dauod Arif, Abdul Waheed, Feroze Sidhwa, Subhasis Misra, Nabin Raj Karki, Nagla Abdel Karim, Ludimila Cavalcante, Asad Ullah
-
Prevalence and risk factors of thyroid nodules in breast cancer women with different clinicopathological characteristics: a cross-sectional study Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-12 Chen-yu Ma, Xin-yu Liang, Liang Ran, Lei Hu, Fan-ling Zeng, Rui-ling She, Jun-han Feng, Zhi-yu Jiang, Zhao-xing Li, Xiu-quan Qu, Bai-qing Peng, Kai-nan Wu, Ling-quan Kong
-
Exploring research progress in studying serum exosomal miRNA-21 as a molecular diagnostic marker for breast cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-11 Hang Li, Xiao-jing Tie
Breast cancer is one of the most prevalent malignancies affecting women globally and poses a significant public health challenge. Early clinical detection plays a pivotal role in providing optimal treatment opportunities and favorable prognoses, crucial for reducing breast cancer mortality and enhancing patients’ quality of life. Therefore, the timely identification and diagnosis of breast cancer are
-
Explainable and visualizable machine learning models to predict biochemical recurrence of prostate cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-11 Wenhao Lu, Lin Zhao, Shenfan Wang, Huiyong Zhang, Kangxian Jiang, Jin Ji, Shaohua Chen, Chengbang Wang, Chunmeng Wei, Rongbin Zhou, Zuheng Wang, Xiao Li, Fubo Wang, Xuedong Wei, Wenlei Hou
-
Heterogeneity and interplay: the multifaceted role of cancer-associated fibroblasts in the tumor and therapeutic strategies Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-11 Qiaoqiao Liu, Fei Yao, Liangliang Wu, Tianyuan Xu, Jintong Na, Zhen Shen, Xiyu Liu, Wei Shi, Yongxiang Zhao, Yuan Liao
-
Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-11 Yi Yu, Tao Wu, Wei Gan, Can Liu, Ran Zhang, Jinxiu Zheng, Jianping Xiong, Jun Chen, Junhe Li
-
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-10 Antonio Juan-Ribelles, Francisco Bautista, Adela Cañete, Alba Rubio-San-Simón, Anna Alonso-Saladrigues, Raquel Hladun, Susana Rives, Jose Luís Dapena, Jose María Fernández, Álvaro Lassaletta, Ofelia Cruz, Gemma Ramírez-Villar, Jose Luís Fuster, Cristina Diaz de Heredia, Miguel García-Ariza, Eduardo Quiroga, María del Mar Andrés, Jaime Verdú-Amorós, Antonio Molinés, Blanca Herrero, Mónica López, Catalina
-
The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-10 Wenxin Da, Ziyu Song, Xiaodong Liu, Yahui Wang, Shengjun Wang, Jie Ma
-
Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-10 Song Mi, Yunxin Yang, Xin Liu, Shaotong Tang, Ning Liang, Jinyue Sun, Chao Liu, Qidong Ren, Jihong Lu, Pingping Hu, Jiandong Zhang
-
Evolution of radiation-induced dermatitis treatment Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-09 Deng Guangmei, He Weishan, Liu Wenya, Wu Fasheng, Chen Jibing
-
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-09 Lidan Chang, Dandan Liu, Xuyan Zhao, Luyao Dai, Xueting Ren, Qian Hao, Peinan Liu, Hao Wu, Xiaobin Ma, Huafeng Kang
-
Construction of a disulfidptosis-related glycolysis gene risk model to predict the prognosis and immune infiltration analysis of gastric adenocarcinoma Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-08 Zhaohui Liao, Zhengyuan Xie
-
Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-08 Ying Wang, Yalan Sun, Fang Lu, Xianghong Zhao, Zhenlin Nie, Feng Zhu, Bangshun He
-
Genomic ancestry and cancer among Latin Americans Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-06 Alejandro Ruíz-Patiño, Leonardo Rojas, Jairo Zuluaga, Oscar Arrieta, Luis Corrales, Claudio Martín, Sandra Franco, Luis Raez, Christian Rolfo, Natalia Sánchez, Andrés Felipe Cardona
Latin American populations, characterized by intricate admixture patterns resulting from the intermingling of ancestries from European, Native American (NA) Asian, and African ancestries which result in a vast and complex genetic landscape, harboring unique combinations of novel variants. This genetic diversity not only poses challenges in traditional population genetics methods but also opens avenues
-
Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-05 Ana Luzarraga Aznar, Vicente Bebia, Natalia Rodriguez Gomez-Hidalgo, Carlos López-Gil, Marta Miguez, Eva Colas, Asunción Pérez-Benavente, Antonio Gil-Moreno, Silvia Cabrera
-
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-05 Álvaro Rodríguez-Lescure, Javier Gallego, Pilar Garcia-Alfonso, Bartomeu Massuti, Raúl Márquez, Lourdes Calvo, Pedro Sánchez-Rovira, Antonio Antón, José Ignacio Chacón, Eva Ciruelos, Jose Juan Ponce, Ana Santaballa, Manuel Valladares-Ayerbes, María Rosario Dueñas, Vicente Alonso, Jorge Aparicio, Sara Encinas, Luis Robles, María José Escudero, Rosalía Caballero, Susana Bezares, Juan de la Haba-Rodriguez
Background Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT. Methods This prospective observational study conducted by GEICAM Spanish Breast Cancer Research Group included metastatic breast (MBC) or colorectal (mCRC) cancer patients treated with bevacizumab-containing
-
In vivo safety evaluation method for nanomaterials for cancer therapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-04
Abstract Nanomaterials are extensively used in the diagnosis and treatment of cancer and other diseases because of their distinctive physicochemical properties, including the small size and ease of modification. The approval of numerous nanomaterials for clinical treatment has led to a significant increase in human exposure to these materials. When nanomaterials enter organisms, they interact with
-
Fertility preservation in hematological cancer patients Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-04 Dan Li, Yi-jun Zhao, Qian Wang, Man-wei Chu, Juan-ke Xie, Cui-lian Zhang
Among adolescents and young adults, hematological malignancies are the most common malignancies. Although the survival rate of hematological malignancies in young patients has been dramatically improved, due to the continuous improvement and development of tumor diagnosis and treatment options, cytotoxic therapies can significantly reduce a patient’s reproductive capacity and cause irreversible infertility
-
Machine learning-driven prediction of brain metastasis in lung adenocarcinoma using miRNA profile and target gene pathway analysis of an mRNA dataset Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-03
Abstract Background Brain metastasis (BM) is common in lung adenocarcinoma (LUAD) and has a poor prognosis, necessitating predictive biomarkers. MicroRNAs (MiRNAs) promote cancer cell growth, infiltration, and metastasis. However, the relationship between the miRNA expression profiles and BM occurrence in patients with LUAD remains unclear. Methods We conducted an analysis to identify miRNAs in tissue
-
Development and validation of a novel scoring system based on a nomogram for predicting inadequate bowel preparation Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-02 Xiaxia Zhao, Yanglin Pan, Jinyong Hao, Jie Feng, Zhongyuan Cui, Huimin Ma, Xiaojun Huang
Background and aims Adequate bowel preparation (BP) is crucial for the diagnosis of colorectal diseases. Identifying patients at risk of inadequate BP allows for targeted interventions and improved outcomes. We aimed to develop a model for predicting inadequate BP based on preparation-related factors. Methods Adult outpatients scheduled for colonoscopy between May 2022 and October 2022 were enrolled
-
Identification and validation of an immune-derived multiple programmed cell death index for predicting clinical outcomes, molecular subtyping, and drug sensitivity in lung adenocarcinoma Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-02 Chunhong Li, Jiahua Hu, Xiling Jiang, Haiyin Tan, Yiming Mao
Objectives Comprehensive cross-interaction of multiple programmed cell death (PCD) patterns in the patients with lung adenocarcinoma (LUAD) have not yet been thoroughly investigated. Methods Here, we collected 19 different PCD patterns, including 1911 PCD-related genes, and developed an immune-derived multiple programmed cell death index (MPCDI) based on machine learning methods. Results Using the
-
Prognostic model based on B cell marker genes for NSCLC patients under neoadjuvant immunotherapy by integrated analysis of single-cell and bulk RNA-sequencing data Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-02
Abstract Background Neoadjuvant immunotherapy has evolved as an effective option to treat non-small cell lung cancer (NSCLC). B cells play essential roles in the immune system as well as cancer progression. However, the repertoire of B cells and its association with clinical outcomes remains unclear in NSCLC patients receiving neoadjuvant immunotherapy. Methods Single-cell RNA sequencing (scRNA-seq)
-
Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC) Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-01
Abstract Background Limited data exist on the prognostic significance of the chronology of VTE in patients with PDAC. Methods Medical data and survival characteristics of patients treated for PDAC from 2019 to 2021 were retrospectively reviewed. Early VTE was defined as occurring within the three months of PDAC diagnosis. Results 197 patients were included, 54 (27.4%) developed a VTE. Early appearance of
-
A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-01 Zehui Jiang, Wenxuan Sun, Rui Du, Rui Yang
First-in-human (FIH) dose-escalation trials on oncology should prioritize safety and emphasize efficacy. We reviewed the FIH trials of 67 anti-tumor products approved by the Food and Drug Administration between 2018 and 2023 and found that the “3 + 3” design remains the predominant dose-escalation method (66.2%). The number of patients receiving sub-therapeutic doses is positively correlated with the
-
Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-01 Óscar Muñoz Muñoz, Elías Gomis Sellés, Blas David Delgado León, Juan Carlos Mateos Perez, Montserrat Baeza Trujillo, Maria Perucha Ortega, José Luis López Guerra, Patricia Cabrera Roldán
-
Interdisciplinary Spanish consensus on a watch-and-wait approach for rectal cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-01 Maria Jose Safont, Roberto García-Figueiras, Ovidio Hernando-Requejo, Rosa Jimenez-Rodriguez, Jorge Lopez-Vicente, Isidro Machado, Juan-Ramon Ayuso, Marco Bustamante-Balén, M. Victoria De Torres-Olombrada, José Luis Domínguez Tristancho, Mª Jesús Fernández-Aceñero, Javier Suarez, Ruth Vera
-
Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-01 Xiaoli Yi, Shasha Hu, Meili Ma, Dongshuai Huang, Yan Zhang
-
Tumor metabolic crosstalk and immunotherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-01 Yiwen Zhang, Yueli Nie, Xiyu Liu, Xitian Wan, Yuanyuan Shi, Keyong Zhang, Pan Wu, Jian He
-
Myelodysplastic syndromes mortality in Spain: a comprehensive age-period-cohort and joinpoint analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-04-01 Reyes María Martín-Rojas, Lucía Cayuela, Francisco Martín-Domínguez, Aurelio Cayuela
-
Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-28 Alejandro Falcón González, Josefina Cruz Jurado, Elisenda Llabrés Valenti, Rocío Urbano Cubero, Maria Carmen Álamo de la Gala, María Antonia Martínez Guisado, Rocío Álvarez Ambite, Carlos José Rodríguez González, Marta Amérigo Góngora, Lourdes Rodríguez Pérez, Pilar López Álvarez, Pedro Sánchez Rovira, Encarnación González Flores, Fernando Henao Carrasco, Juan Bayo Calero, María Valero Arbizu, Alicia
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-26 Aylen Vanessa Ospina, Sergio Bolufer Nadal, José Luis Campo-Cañaveral de la Cruz, Jose Luis González Larriba, Ivan Macía Vidueira, Bartomeu Massutí Sureda, Ernest Nadal, Florentino Hernando Trancho, Antonio Álvarez Kindelán, Edel Del Barco Morillo, Reyes Bernabé Caro, Joaquim Bosch Barrera, Virginia Calvo de Juan, Joaquin Casal Rubio, Javier de Castro, Ángel Cilleruelo Ramos, Manuel Cobo Dols, Manuel
-
Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-26 Tianqi An, Qiu Hui, Hong Zong, Linhua Liu, Xinguang Cao, Rui Li, Shuang Hu, Yiyi Liu, Jia Li, Ruihua Zhao
-
Logistic regression and other statistical tools in diagnostic biomarker studies Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-26 Dina Mohamed Ahmed Samir Elkahwagy, Caroline Joseph Kiriacos
-
The prognostic value of vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma: a systematic review and meta-analysis Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-25 Miaomiao Wang, Liang Cao, Yinzhong Wang, Hongliang Huang, Xiaoxue Tian, Junqiang Lei
-
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-22 Helena Pla, Eudald Felip, Verónica Obadia, Sonia Pernas, Gemma Viñas, Mireia Margelí, Roser Fort-Culillas, Sonia Del Barco, Nuria Sabaté, Eduard Fort, Clara Lezcano, Beatriz Cirauqui, Vanesa Quiroga, Agostina Stradella, Miguel Gil Gil, Anna Esteve, Sabela Recalde
-
Screening and treatment of latent tuberculosis in patients with solid tumors and systemic cancer therapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-21 Miguel Borregón, David Sánchez, Elia Martínez
Introduction Tuberculosis is one of the infectious diseases with greater morbidity and mortality worldwide. Cancer causes an important immunosuppression with increased risk of infections. There is an enlarged bidirectional incidence between tuberculosis and cancer, mainly due to latent tuberculosis. Guidelines review There is great discrepancy between recommendations for screening and prophylaxis of
-
Zebrafish live imaging: a strong weapon in anticancer drug discovery and development Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-21 Tiancheng Zhan, Wanqian Song, Guo Jing, Yongkang Yuan, Ning Kang, Qiang Zhang
-
Molecular characterization of Chinese patients with small bowel adenocarcinoma Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-21 Bryan Jin, Bin Lv, Zhengqing Yan, Wenshuai Li, Huan Song, Haoshu Cui, Yao Liu, Bin Zhong, Xin Shen, Xiao Li, Bei Zhang, Shiqing Chen, Wanwei Zheng, Jie Liu, Feifei Luo, Zhongguang Luo
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-21
Abstract Objectives The S-REAL study aimed to assess the effectiveness of durvalumab as consolidation therapy after definitive chemoradiotherapy (CRT) in a real-world cohort of patients with locally advanced, unresectable stage III non-small cell lung cancer (LA-NSCLC) included in a Spanish early access program (EAP). Methods In this multicentre, observational, retrospective study we analysed data
-
Current approaches in glioblastoma multiforme immunotherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-21 Marjan Aghajani, Nazila Jalilzadeh, Ali Aghebati-Maleki, Amirhossein Yari, Peyman Tabnak, Amirhossein Mardi, Hossein Saeedi, Leili Aghebati-Maleki, Behzad Baradaran
-
Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-21 Ana Isabel Martin-Quesada, Elisenda Llabres-Valentí, Cristina María Montesdeoca-Godoy, Carla Martín-Abreu, Cristina Alemán-Sánchez, Natalia Rodríguez-Pérez, Alicia Herrero-Márquez, Josefina Cruz-Jurado, María Hernández-Sosa, Melody Marrero-García, Cristina Victoria DelPino-Hernández, Samuel José Hernández-Sarmiento, Alejandra Rodríguez-Capote, Lina Pérez-Méndez, Isaac Núñez-Hernández
Purpose Tri-weekly carboplatin is an established neoadjuvant treatment for triple-negative breast cancer, enhancing pathological complete response (pCR) and overall survival. This study explores if weekly carboplatin provides lower toxicity and comparable pCR rates. Methods/patients A retrospective multicenter study (January 2021 to March 2023) compares outcomes of weekly and tri-weekly carboplatin
-
Partial-accelerated irradiation with stereotactic radiotherapy at a dose of 30 Gy in 5 fractions in early breast cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-20 Javier Albendea Roch, Javier T. Anchuelo Latorre, M. Piedad Galdós Barroso, P. Navarrete Solano, Ana Laura Rivero Pérez, Frandeina Pinto Guevara, Mara García Lamela, Javier Olloqui Urroz, M. Díaz de Tuesta, Jesús Mazaira, Pedro Muñoz, Pedro J. Prada Gómez
Purpose To evaluate feasibility of accelerated partial breast irradiation (APBI) using stereotactic radiotherapy (SBRT) Thirty Gy delivered in 5 fractions for patients with early breast cancer. Methods Between January 1st, 2018, and December 31s, 2022, we conducted 117 treatments for patients with early-stage breast cancer. All patients underwent conservative surgery followed by APBI using stereotactic
-
Current status of neoadjuvant immunotherapy for the treatment of gastric cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-20 Xijie Zhang, Bo Liu, Rui Wang, Xin Li, Wence Zhou
Gastric cancer is one of the most prevalent malignant tumors worldwide, characterized by high incidence and mortality rates. At present, comprehensive surgical treatment has enhanced the prognosis of locally advanced gastric cancer patients significantly. However, the postoperative recurrence rate remains high, and the long-term survival for patients is sub-optimal. In recent years, immunotherapy has
-
Advances in tumor vascular growth inhibition Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-20
Abstract Tumor growth and metastasis require neovascularization, which is dependent on a complex array of factors, such as the production of various pro-angiogenic factors by tumor cells, intercellular signaling, and stromal remodeling. The hypoxic, acidic tumor microenvironment is not only conducive to tumor cell proliferation, but also disrupts the equilibrium of angiogenic factors, leading to vascular
-
Circulating serum exosomes i-tRF-AspGTC and tRF-1-SerCGA as diagnostic indicators for non-small cell lung cancer Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-19 Jiefei Peng, Yue Zhang, Guangfei Zhou, Luolin Shao, Lin Li, Zhijun Zhang
-
Contouring aid tools in radiotherapy. Smoothing: the false friend Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-17 Jordi Marruecos Querol, Diego Jurado-Bruggeman, Anna Lopez-Vidal, Ricard Mesía Nin, Jordi Rubió-Casadevall, Maria Buxó, Aranzazu Eraso Urien
-
Association between thyroid disorders and extra-thyroidal cancers, a review Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-15 Xin Jia, Jingru Li, Zongliang Jiang
-
The diagnostic and prognostic value of exosomal microRNAs in lung cancer: a systematic review Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-15 Bingbing Yang, Xiaoqi Xin, Xiaoqing Cao, Lubanga Nasifu, Zhenlin Nie, Bangshun He
-
Enhanced outcomes in residual or recurrent craniopharyngioma: evaluating combined gamma knife and phosphorus-32 brachytherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-15 Jie Ma, Tao Chen, Jianning Zhang, Weidong Cao, Gan Gao, Xinguang Yu, Hongwei Wang
-
Assessment of TUFT1 and Rac1-GTP levels in triple-negative breast cancer patients: clinical and pathological correlations Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-13 Su-fang Shi, Rui-xi Cai, Yan-fei Ren, Yong Li, Shuo Li, Tian-lu Yin, Dong-xiao Jia, Yong-jun Li
-
Clinical risk prediction model and external validation of positive surgical margin in laparoscopic radical prostatectomy based on MRI lesion location Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-13 Xin Chen, Chaozhong Wang, Yongchang Chen, Chengbo Qian, Renpeng Huang, Jie Bao, Yuxin Lin, Jianquan Hou, Yuhua Huang, Xuedong Wei
-
Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-13 Yuanliang Zhou, Jingchao Li, Yankang Li, Guangchuan Deng, Qi Wang, Hongyue Qin, Jianbin Li, Zhenxiang Li
-
Sarcopenia among treated cancer patients before and after neoadjuvant chemotherapy: a systematic review and meta‐analysis of high-quality studies Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-12 Yuanhao Su, Yongke Wu, Cheng Li, Tingkai Sun, Yunhao Li, Zhidong Wang
-
Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-12 Cheng Luo, Shuhang Luo, Wumier Wusimanjiang, Zongren Wang, Ping Liu, Bin Wang, Dan Yuan, Hao Lin, Abai Xu, Nan Deng, Kaihui Wu, Xuejin Zhu, Peng Xu, Junxing Chen, Bin Huang
-
Integrated analysis reveals an aspartate metabolism-related gene signature for predicting the overall survival in patients with hepatocellular carcinoma Clin. Transl. Oncol. (IF 3.4) Pub Date : 2024-03-12 Juanyi Shi, Kai Wen, Sintim Mui, Huoming Li, Hao Liao, Chuanchao He, Yongcong Yan, Zhenyu Zhou, Zhiyu Xiao